Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

7.350 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Xeris Biopharma Announces Results of the Extended Evaluation of Recorlev® (Levoketoconazole) From the Phase 3 Sonics Study Published in the European Journal of Endocrinology
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
10 Best Medical Stocks Under $5 ↗
The medical industry is one of the most lucrative sectors globally, and it is one that sees the highest spending in terms of research and development, and breakthrough advances through keeping up the... 
Via Talk Markets
News headline image
Xeris Biopharma Posts Encouraging Data From Reformulated Thyroid Hormone Deficiency Treatment In Healthy Participants ↗
 
Via Benzinga
News headline image
Xeris Biopharma Announces Positive Topline Phase 1 Clinical Data of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121); Hosts Conference Call and Webcast
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Earnings Scheduled For May 11, 2022 ↗
Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter. 
Via Benzinga
News headline image
Earnings Scheduled For March 10, 2022 ↗
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
News headline image
121 Stocks That Hit Their 52-Week Low ↗
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Xeris Biopharma Reports Second Quarter Financial Results and Upcoming Events
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Earnings Scheduled For August 10, 2022 ↗
Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is estimated to report earnings for its second quarter. 
Via Benzinga
News headline image
Xeris Biopharma to Report Second Quarter 2022 Financial Results on August 10, 2022
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris’ Commercialization Partner for Ogluo®, Tetris Pharma Ltd, to Be Acquired by Arecor Therapeutics
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
It's time for another breakdown of the biggest pre-market stock movers as we go over the latest news for Thursday morning. 
Via InvestorPlace
News headline image
27 Stocks Moving in Thursday's Pre-Market Session ↗
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday IPO. 
Via Benzinga
News headline image
Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data at AACE Annual Meeting May 12-14
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
73 Biggest Movers From Yesterday ↗
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Xeris Biopharma Holdings: Q1 Earnings Insights ↗
Xeris Biopharma Holdings (NASDAQ:XERS) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Pharmaceuticals's Earnings Outlook ↗
Xeris Pharmaceuticals (NASDAQ:XERS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022 ↗
 
Via Benzinga
News headline image
Analyst Ratings For Xeris Biopharma Holdings ↗
Xeris Biopharma Holdings (NASDAQ:XERS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
News headline image
Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Recap: Xeris Biopharma Holdings Q4 Earnings ↗
Xeris Biopharma Holdings (NASDAQ:XERS) reported its Q4 earnings results on Thursday, March 10, 2022 at 08:00 AM. Here's what investors need to know about the... 
Via Benzinga
News headline image
A Preview Of Xeris Pharmaceuticals's Earnings ↗
Xeris Pharmaceuticals (NASDAQ:XERS) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement.... 
Via Benzinga
News headline image
Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
From Xeris Biopharma Holdings
Via Business Wire
News headline image
Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
18 Stocks Moving in Monday's Pre-Market Session ↗
Gainers FGI Industries Ltd. (NASDAQ: FGI) rose 92.8% to $7.27 in pre-market trading after jumping 19% on Friday. The company, last week, priced its IPO at $6 per... 
Via Benzinga
News headline image
Xeris Biopharma Eyes High End Of FY21 Sales Outlook ↗
Xeris Biopharma Holdings Inc (NASDAQ: XERS) has reaffirmed its preliminary 2021 pro forma sales at a high-end of $76 million - $80 million guidance, approximately... 
Via Benzinga
News headline image
Xeris Biopharma Reaffirms 2021 Guidance and Provides Business Update
From Xeris Biopharma Holdings, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.